Anteris Technologies Global Corp. — AGM Information 2009

Nov 10, 2009

==> picture [596 x 64] intentionally omitted <==

Innovative BioMedical Devices ABN 35 088 221 078

bioMD Limited Level 11, 225 St Georges Terrace Perth, Western Australia 6000 PO Box 7209, Cloisters Square Western Australia 6850

Telephone (08) 9262 6777 Facsimile (08) 9322 3433 ABN 35 088 221 078 www.biomd.com.au

ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE

1 of 4 pages

11 November 2009

Company Announcements Office Australian Stock Exchange Limited 10th Floor, 20 Bond Street SYDNEY NSW 2000

CHAIRMAN’S ADDRESS

The Directors of bioMD Limited are pleased to announce the Chairman’s Address for the 6[th] Annual General Meeting of the Company to be held today.

Yours faithfully

==> picture [79 x 59] intentionally omitted <==

Caroline Bentley Company Secretary

==> picture [596 x 42] intentionally omitted <==

==> picture [116 x 61] intentionally omitted <==

CHAIRMAN’S ADDRESS

SIXTH Annual General Meeting of bioMD Ltd

11 November 2009 – The Somerset Hotel, 185 St George’s Terrace, Perth

OVERVIEW:

The past year has seen bioMD advance its progression towards commercialisation of the ADAPT tissue engineering process, through our human clinical trial program and a focus on establishing commercial partnerships with global medical device companies.

During 2008/09,

• The Phase II Human clinical trial concluded in South Africa, with 30 patients now having been implanted with CardioCel patches in cardiovascular surgical procedures. Importantly we will now have clinical data from the 6 and 12 month follow-up examinations which will provide us with excellent clinical results to use in the regulatory approvals process. The CardioCel patch performed to expectations in this chronically ill patient group. The clinical data from this study will also provide hard clinical evidence to the global tissue heart valve companies with whom we are currently in discussions;

• We have also commenced an Australian human clinical trial, to prove the efficacy of our Gynecel patch in pelvic floor surgical reconstruction procedures, with the first patient implant having been undertaken in September.

The Gynecel patch is produced using our ADAPT tissue engineering process, and is specifically targeted for urogynaecological surgical applications. This trial will see 20 patients implanted and then followed for 24 months;

• We are continuing our research collaboration to produce a transcatheter heart valve incorporating ADAPT tissue engineered tissue on heart valves. The initial prototypes have been produced with pre-clinical animal trials due to commence shortly;

• We have undertaken research in collaboration with a leading Australian children’s hospital to use ADAPT tissue engineered biomaterial patches as an alternative to using the patient’s own pericardial tissue;

• We have also furthered our research and development program into mesenchymal stem cells using growth factors seeded onto ADAPT treated patches; and

• The Company raised $860,000 in a fully subscribed rights issue to shareholders; and welcomed Ochre Health Group as a substantial holder as a result of its investment.

Turning to the financial results:

The operating loss of the Group for the year ended 30 June 2009 amounted to a loss of $1.1 million, compared to the previous year of a loss of $1.3 million. We have again focused on keeping

administration costs to a minimum and cash at bank as at year-end was $1.25 million.

During the year our Share Registry, Computershare, wrote to all of our shareholders advising them of legislation changes and giving them the choice to opt out of receiving a hard copy of bioMD’s annual report. Our annual report is available on the company’s website at www.biomd.com.au, and we anticipate this initiative will save the company several thousand dollars per year.

I would like to acknowledge my fellow board members, our staff and the advisory team for their efforts during the year.

Looking forward, bioMD is pursuing its principle objective to commercialise our ADAPT technology for use in broader surgical applications. We propose to issue up to 30 million new shares to fund a feasibility for the establishment of a commercial production facility within Australia, develop a marketing strategy for

international expansion and complete regulatory approvals. A notice of a general meeting is being sent to all shareholders today seeking approval of the proposed capital raising, and we look forward to seeing you at that meeting which is to be held on Thursday 10 December 2009 at 11am.

Thank you to our shareholders for your continuing interest in and support for the Company.

Robert N. Scott

Chairman